// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Previous and posterior psychopharmacological treatment in bariatric surgery patients

M.Angelats - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Fluoxetine

Analysis of exhaled breath of lung cancer patients using infrared spectroscopy.

Tony J. Reiman - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Lung cancer as a subsequent neoplasm: A report from the Childhood Cancer Survivor Study (CCSS).

Taumoha Ghosh - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

From ‘Big 4′ to ‘Big 5′: A review and epidemiological study on the relationship between psychiatric disorders and World Health Organization preventable diseases

G.Chartier - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Real-world healthcare resource utilization and costs among relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients receiving ibrutinib or chemoimmunotherapy (CIT).

Nilanjan Ghosh - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ibrutinib

Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)-like melanoma.

Thiago Pimentel Muniz - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Improving dual diagnosis care in acute psychiatric inpatient settings through education

K.Bonnie - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Intellectual developmental disorders, autism, and schizophrenia spectrum: New boundaries in the neurodevelopmental perspective

M.Bertelli - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).

Nizar J. Bahlis - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hyaluronidase

Effect of the oral CXCR4 inhibitor X4-136 on tumor control and side effects in cervical cancer treated with radiotherapy and concurrent chemotherapy.

Naz Chaudary - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cisplatin

Consensus molecular subtypes in colorectal cancer differ by geographic region.

Krittiya Korphaisarn - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Sixteen-year population-based cohort study of main class International Classification of Diseases associated with psychiatric disorders in a sample under the age of two years

D.Cawthorpe - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Underdiagnosis and undertreament of modifiable cardiovascular risk factors: A Childhood Cancer Survivor Study (CCSS) report.

Eric Jessen Chow - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Use of oncology electronic learning resources to learn about geriatric oncology.

Tina Hsu - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Lauren Christine Harshman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Nivolumab

First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO.

Daniel Vilarim Araujo - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).

Catherine Curran - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Angiotensin II

Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy for breast cancer: Results from a prospective institutional database.

Megan Tesch - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

taxane

Results of a first-in-human phase I study of SRF231, a fully human, high‑affinity anti‑CD47 antibody.

Amita Patnaik - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Recurrent vulvar squamous cell carcinoma: An analysis of clinical outcomes by treatment modality including surgery, chemotherapy, and radiation.

Trish Dinh - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved